Summary & Overview
CPT 0234U: Genomic Unity MECP2 Analysis via PCR-free WGS
CPT code 0234U identifies a proprietary genomic laboratory test — Genomic Unity® MECP2 Analysis from Variantyx Inc. — that uses PCR-free whole genome sequencing and algorithmic analysis to detect variants in the MECP2 gene, which are clinically relevant for disorders such as Rett syndrome. As a PLA code, 0234U is specific to a single manufacturer’s test and signals a unique, high-complexity diagnostic service in molecular genetics. Nationally, PLA CPT codes like 0234U matter because they enable distinct tracking, pricing, and coverage determinations for proprietary genomic assays.
Key payers discussed include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find: an explanation of the clinical and laboratory context for the test; the typical site and service type for billing and operational planning; and guidance on what information is available versus missing. This publication outlines benchmarks and policy considerations relevant to proprietary genomic testing codes, summarizes payer coverage landscape where available, and describes clinical indications tied to MECP2 variant analysis. Data not available in the input are noted explicitly in relevant sections.
Billing Code Overview
CPT code 0234U is a Proprietary Laboratory Analyses (PLA) code for the Genomic Unity® MECP2 Analysis from Variantyx Inc. The test evaluates the methyl CpG binding protein 2 (MECP2) gene for variants relevant to conditions such as Rett syndrome using a PCR-free whole genome sequencing (WGS) platform with algorithmic data analysis.
Service type: Genomic laboratory testing (proprietary WGS-based gene analysis)
Typical site of service: Clinical laboratory or reference diagnostic laboratory
Clinical & Coding Specifications
Clinical Context
A typical patient is a female child or adolescent presenting to a pediatric neurology or medical genetics clinic with global developmental delay, regression of acquired skills, characteristic hand stereotypies, slowed head growth, and/or loss of purposeful hand use — features suggestive of Rett syndrome or other MECP2-related disorders. The clinician documents a detailed history and neurological exam, orders diagnostic testing including genetic evaluation, and counsels the family on test purpose and specimen options (blood or saliva). A blood draw or saliva kit is collected in clinic or at an affiliated phlebotomy site and sent to Variantyx Inc. for the Genomic Unity® MECP2 Analysis. Laboratory processing uses a PCR-free whole genome sequencing (WGS) platform with algorithmic analysis focused on the MECP2 gene to detect sequence variants and structural changes relevant to diagnosis. Results are reported to the ordering clinician, who reviews variant interpretation, updates the medical record, provides genetic counseling, and coordinates cascade testing or management as indicated. Typical site of service includes outpatient hospital-based genetics or neurology clinic, freestanding outpatient laboratory specimen collection center, or an accredited clinical laboratory performing specialized genetic testing.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
00 | No modifier — default | Use when no specific modifier applies to the laboratory service. |